MedTrace Logo

Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism

NCT03179787 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 528

Last updated 2021-09-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and effectiveness of aripiprazole in patients with autism in the real world clinical setting in Japan.

Conditions

Interventions

DRUG

Aripiprazole oral product

oral administration of aripiprazole

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Pharmacovigilance · Otsuka Pharmaceutical Co., Ltd.

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-01
Primary Completion
2020-03-17
Completion
2020-07-06

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03179787 on ClinicalTrials.gov